BD Unveils Critical Dates for Shareholders
BD (Becton, Dickinson and Company) (NYSE: BDX), a leader in global medical technology, has announced pivotal dates regarding the upcoming spin-off of its Biosciences & Diagnostic Solutions business. The board has officially designated February 5, 2026, as the record date for shareholders. This transaction marks a significant step in BD's transformation, allowing it to focus on core markets while enhancing shareholder value.
Details of the Spin-Off and Merger
Following the spin-off, BD’s biosciences entity is set to merge with Waters Corporation (NYSE: WAT) in a Reverse Morris Trust transaction. The anticipated completion of this merger is scheduled for February 9, 2026, contingent on the fulfillment of standard closing conditions.
Shareholder Benefits
Under the terms of the agreement, BD stands to receive an impressive $4 billion in cash. More intriguingly, BD shareholders will obtain shares of Waters common stock reflecting 39.2% of the new company on a fully diluted basis. Meanwhile, current Waters shareholders will control 60.8% of the combined entity. Specific share allocation for BD shareholders will be disclosed at transaction closing.
No Action Required from Shareholders
Importantly, BD common stockholders need to take no action to receive their shares in the newly merged entity. As long as they hold onto their shares through the record date, they will automatically benefit from this significant transaction. Post-merger, shareholders will maintain the same number of BD shares, alongside their newly acquired Waters shares.
Expectations Post-Merger
After the completion of the deal, it is expected that BD's stock price will reflect the transfer of the Biosciences & Diagnostic Solutions business to Waters Corporation. This evolution signals a strategic shift in how BD will operate and compete in the medical technology marketplace.
Regulatory Approvals and Trading Notices
BD has successfully obtained a Private Letter Ruling from the IRS concerning the federal income tax implications of this transaction. Additionally, approval for the share issuance has been granted by Waters shareholders. Beginning on February 5, 2026, trading in BD common stock will incorporate "due bills", granting holders the right to receive the upcoming distribution of shares.
Advice for Investors
It is critical for investors to consult with their financial and tax advisors to understand the ramifications of selling their BD shares, including effects on their rights to Waters common stock derived from this distribution.
About BD
BD is a premier global medical technology company that is committed to advancing the world of health™. With over 70,000 dedicated employees, the company is focused on improving medical discovery and enhancing diagnostic processes, ultimately fostering better patient care. BD collaborates with healthcare entities worldwide to tackle urgent global health challenges and invest in innovative solutions critical for modern healthcare delivery.
Frequently Asked Questions
What is the spin-off date for BD's Biosciences business?
The record date for the spin-off is set for February 5, 2026, with the merger completion expected on February 9, 2026.
How will shareholders benefit from the merger?
Shareholders will receive shares of Waters common stock equivalent to 39.2% of the combined entity, representing a substantial financial opportunity.
Do BD shareholders need to take action to receive shares?
No action is required from BD shareholders. As long as they hold shares by the record date, they will automatically receive the new shares.
What should investors do ahead of the merger?
Investors should consult financial and tax advisors to understand implications of buying or selling BD shares related to the spin-off and merger.
How does BD's future look after the merger?
The merger is expected to enhance BD's strategic focus, allowing for greater innovation and efficiency in the medical technology sector.
